



Global epidemiology of injecting drug use, HIV, viral hepatitis and harm reduction services among people who inject drugs

Medicine

National Drug and Alcohol Research Centre



@SarahLarney
@INHepSU
#INHSU17


Acknowledgements and disclosures

- Collaborators: Louisa Degenhardt, Jason Grebely, Matt Hickman, Amy Peacock, Janni Leung, Peter Vickerman
- Evan Cunningham produced the maps for this presentation
- GBD substance use disorders team – IHME, UQ, NDARC
- Funding:
 - WHO, UNAIDS, UNODC, Global Fund, OSF (global reviews)
 - Bill & Melinda Gates Foundation (GBD)
 - National Drug and Alcohol Research Centre
- Disclosure:
 - I have received an untied educational grant from Indivior to examine naloxone distribution in Australia.
 - The funders had no role in the projects they funded and had no knowledge of this work.


Key theme

- Existing data are limited in quantity and quality
- Better data are needed to inform and monitor progress towards hepatitis C elimination

Injecting drug use is a global phenomenon



Infectious disease deaths, lifetime history of injecting drug use, 2013




NDARC
National Drug &
Alcohol Research Centre

The Difference is Research

Degenhardt et al., *Lancet Infect. Dis.* 2016

5

Infectious disease disability-adjusted life-years, lifetime injecting drug use, 2013




NDARC
National Drug &
Alcohol Research Centre

The Difference is Research

Degenhardt et al., *Lancet Infect. Dis.* 2016

6

Proportion of HIV DALYs, lifetime injecting drug use, 2013




NDARC
National Drug & Alcohol Research Centre

The Difference is Research

7

Proportion of HCV DALYs lifetime injecting drug use, 2013




NDARC
National Drug & Alcohol Research Centre

The Difference is Research


8

Data on HIV and viral hepatitis prevalence among recent injectors


HIV prevalence among people who inject drugs: mostly well characterised, but also critical gaps



Anti-HCV prevalence among people who inject drugs: greatly improved




Very few studies of viremic HCV infection among people who inject drugs




Coverage of harm reduction programmes

Needle and syringe program implementation



Opioid substitution therapy implementation



Harm reduction in prisons and jails

- NSP in at least one prison: Armenia, Kyrgyzstan, Moldova, Tajikistan, Germany, Luxembourg, Spain, Switzerland
- OST in at least one prison in 52 countries
 - Usually very limited

From: Harm Reduction International, *Global State of Harm Reduction 2016*

Conclusions: Key epidemiological research that is needed

- Injecting drug use population sizes
 - By age, sex, racial/ethnic minority status
 - Age of onset, duration of injecting
- Prevalence of HCV testing, treatment access, cure, active HCV infection, re-infection

Forthcoming:

Degenhardt et al. Global epidemiology of injecting drug use, HIV and viral hepatitis among people who inject drugs. *Lancet Global Health*

Larney et al. Global, regional and national coverage of HIV and hepatitis C prevention and management in people who inject drugs. *Lancet Global Health*

s.larney@unsw.edu.au